Shift towards Orphan Drugs is anticipated to Drive Demand Growth in Rare Neurological Disease Treatment Market
The global rare neurological disease treatment market is projected to expand at a stellar CAGR of over 8.5% and is anticipated to grow 2.3x between 2018 and 2028. Over the last decade, the prevalence of rare diseases, evolving trend of orphan drugs and increasing expenditure on healthcare has provided a huge momentum to overall sales of rare neurological drugs. As a result, the global sales within the rare neurological disorder treatment market has achieved a new milestone and surpassed the valuation of US$ 6.5 Bn in 2019. In addition, due to their relatively high market value share and growth rate, the rare neurological disease treatment market is estimated to remain the most lucrative market within the rare disease treatment markets. Furthermore, rapid developments in healthcare and dramatic socioeconomic changes resulting in modified lifestyles is also giving opportunities to manufacturers to expand their footprint within the rare neurological disease treatment market
Revenue Share in Injectable Segment is forecast to Jump ~180 BPS
Ongoing research and development activities in the field of rare neurological disease treatment are proliferating on the back of increasing demand for orphan drugs. This is anticipated to create an absolute dollar opportunity of US$ 8.1 Bn between 2018 and 2028. The promulgation of disposable injectors is rapidly covering all aspects of the rare neurological disease treatment market. Hence, injectable drug delivery devices are acquiring a leading position. Furthermore, increasing demand for patient friendly parenteral drug delivery systems and increasing number of surgical treatments are expected to boost the growth of injectable segment over the forecast period.
Access our intuitive market intelligence on the neurological disease treatment market, request for a report sample here
Biologics Segment to Account for over 40% Market Share in Drug Class Category
A biopharmaceutical revolution is showing its prevalence in pharmaceutical research and development laboratories which is driving industry-wide progress, including the advancement of primary packaging and delivery technologies. Biologics is enabling the treatment of cancers, chronic autoimmune and lifestyle diseases that were previously untreatable. The biologics segment is projected to expand at a CAGR of over 7.5% over the long term forecast period (2018-2028). The key players in the biologics segments are likely to face less competition across the globe on back of the high level of complexity that is associated with the production of biologics
Asia-Pacific to Pave Way for Profitable Alliances for Key Manufacturers
North America is poised to be the leading region in the global rare neurological disease treatment market accounting for a 2/5th market share in 2019 on the back of well-established healthcare infrastructure and continuous emphasis on R&D in drugs and treatment of rare diseases. Changing regional demographics, epidemiology and amplified healthcare coverage plans in regions such as South Asia, East Asia and Latin America are propelling the global rare neurological disease treatment market within these regions. In Europe, the disease treatment industry is mainly bound to various government policies and market strategies. In a bid to attain a competitive edge over the market players at the global platforms, the players in Europe are concentrating on offering product innovations.
To get an exhaustive regional analysis on the neurological disease treatment market, ask an analyst here
Innovations in Value Chain is Setting a New Growth Trajectory for Key Market Actors
The global rare neurological disease treatment market is expected to showcase a consolidated market structure. Key industry giants such as Novartis AG, Pfizer Inc., and Johnson & Johnson Services, Inc. hold more than 50% of share in the global rare neurological disease treatment market and are anticipated to attract more end users in near future owing to its brand positioning across the globe. Manufacturers are focused on developing new therapies to decrease the burden of rare diseases, thus increasing their respective market shares. In addition, innovations across the value chain and drug delivery models is likely to play a vital role in order to gain more penetration in the global market.
Global Rare Neurological Disease Treatment Market – Scope of the Report
The following report provides forecast and analysis of the global rare neurological disease treatment market along with the historical data of 2013, estimated data 2018 and forecast data up to 2028 in terms of value (US$ Mn), according to a Fact.MR study. The research propounds critical trends that are currently influencing growth within the global rare neurological disease treatment market along with several macro-economic indicators. This newly published and insightful report on rare neurological disease treatment sheds light on key dynamics, and their impact on the overall value chain from suppliers to end-users, which are expected to transform the future of the global rare neurological disease treatment market.
The report also comprises the study of current issues with end users and opportunities for rare neurological disease treatment. It also contains value chain analysis, including the key market participants. To provide users of this report with a comprehensive view of the market, we have included a detailed competitive analysis about the key players involved in the market and strategic overviews. The dashboard included in the report provides a detailed comparison of rare neurological disease treatment manufacturers on parameters such as total revenue, product offerings, and key strategies. A list of key companies operating in the rare neurological disease treatment market provided in the report adds to the credibility of this exhaustive research study.
Global Rare Neurological Disease Treatment Market: In-Depth Assessment on Key Segments
The global rare neurological disease treatment market is segmented on the basis of drug class, route of administration, disease indication, distribution channel, and region.
|
Drug Class |
Route of Administration |
Disease Indication |
Distribution Channel |
Region |
|
Anti-depressants |
Injectable |
Alzheimer's Diseases |
Hospital Pharmacies |
North America |
|
Anti-psychotics |
Oral |
Narcolepsy |
Retail Pharmacies and Drug Store |
Latin America |
|
Cholinesterase Inhibitors |
Multiple Sclerosis |
Online Pharmacies |
Europe |
|
|
Biologics |
Amyotrophic Lateral Sclerosis |
South Asia |
||
|
Others (Anti-vertigo, Anti-seizure, etc.) |
Others |
East Asia |
||
|
Oceania |
||||
|
Middle East & Africa |
This taxonomy and the detailed TOC prepared are confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.
Country-specific assessment on demand for rare neurological disease treatment has been provided for each regional market, along with the market size valuation and forecast price point assessment, price index and impact analysis of key regional and country-wise dynamics, which were obtained through quotes from numerous rare neurological disease treatment manufacturers, experts, and suppliers. Y-o-Y growth projections have also been offered on all regional markets incorporated in the report. Moreover, future trends, growth prospects, and other possibilities related to the market have been answered in the report.
The report provides company-level market share analysis, which has been derived on the basis of the company’s annual sales and segmental revenue in all the target disease indications. The market has been forecasted based on constant currency rates. The report provides detailed competitive and company profiles of key participants operating in the global rare neurological disease treatment market. Some of the key competitors operating in the rare neurological disease treatment market are Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc. Bayer AG, GlaxoSmithKline Plc, Sanofi S.A., Allergan Plc, Merck & Co., Inc., and others.
Global Rare Neurological Disease Treatment Market: Research Methodology
A number of primary and secondary sources were consulted during the course of the study. Secondary sources include Factiva, Morningstar and Hoovers, and company annual reports and publications. Comprehensive interviews have been conducted by our analysts, and the intelligence and insights obtained have been used for validating the information gained through secondary research. The report also includes a description of assumptions and acronyms utilized for research purposes. Data gathered has been validated using the triangulation method to offer useful quantitative and qualitative insights into the rare neurological disease treatment market.
A short market viewpoint offered in the report elucidates the macro-economic aspects that influence the growth of the rare neurological disease treatment market, which includes global GDP growth rate, healthcare industry growth rate, prevalence rate of rare diseases, per capita spending on healthcare, number of healthcare facilities by countries, etc. This report serves as an authentic resource of intelligence on the rare neurological disease treatment market, enabling the readers to take fact-based decisions on the future direction of their businesses.
1. Global Rare Neurological Disease Treatment Market - Executive Summary
1.1. Summary of Key Findings
1.2. Summary of Key Statistics
1.3. Treatment Evolution
1.4. Fact.MR Analysis and Recommendations
2. Global Rare Neurological Disease Treatment Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.1.1. Standard Framework For Screening New-Born
3.1.2. Interactive Course To Raise Awareness About Rare Diseases
3.1.3. Patient Groups Are Playing An Active Role In Supporting Coordinated Care
3.1.4. Shift Towards Orphan Drugs
3.1.5. Others
4. Key Success Factors
4.1. Product Adoption / Awareness Analysis
4.2. Product Features Vs. Application Matrix
4.3. Strategic Promotional Strategies, By Key Manufacturers
4.4. Key Market Attributes & Characteristics
4.5. Investment Feasibility Matrix
5. Global Rare Neurological Disease Treatment Pricing Point Analysis
5.1. Regional Pricing Analysis By Drug Class
5.2. Pricing Break-up
5.2.1. Manufacturer Level Pricing
5.2.2. Distributor Level Pricing
5.3. Global Average Pricing Analysis Benchmark
6. Global Rare Neurological Disease Market Demand (in Value US$ Mn) Analysis 2013-2017 and Forecast, 2018-2028
6.1. Historical Market Value (US$ Mn) Analysis, 2013-2017
6.2. Current and Future Market Value (US$ Mn) Projections, 2018-2028
7. Market Background
7.1. Global Rare Disease Treatment Market Outlook, 2018
7.1.1. By Regions
7.1.2. By Disease Indication
7.2. Global Rare Disease Treatment Market Opportunity Assessment
7.3. Regularity Framework by Regions/Key Countries
7.4. Macro-Economic and Forecast Factors
7.4.1. GDP Growth Outlook
7.4.2. Rising per-Capita Healthcare Expenditure
7.4.3. High Prevalence of Rare Neurological Disorders in Developing Countries
7.4.4. Growing Awareness on Rare Neurological Diseases
7.4.5. Increase In Investment on Healthcare Sector by The Pharmaceutical Companies
7.4.6. Rise in Treatment Adoption Rate
7.4.7. Enhanced R&D for Rare Neurological Diseases
7.4.8. Others
7.5. Value Chain Analysis
7.5.1. List of Key Market Manufacturers
7.5.2. List of Key Channel Partners
7.5.3. Profitability Margins
7.6. Market Dynamics
7.6.1. Drivers
7.6.2. Industry Challenges
7.6.3. Opportunities
8. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013 - 2017
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2018 - 2018
8.3.1. Anti-depressants
8.3.2. Anti-psychotics
8.3.3. Cholinesterase Inhibitors
8.3.4. Biologics
8.3.5. Others (Anti-vertigo, anti-seizure)
8.4. Market Attractiveness Analysis By Drug Class
9. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013 - 2017
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2018 - 2018
9.3.1. Injectable
9.3.2. Oral
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2013 - 2017
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2018 - 2018
10.3.1. Alzheimer’s Disease
10.3.2. Narcolepsy
10.3.3. Multiple Sclerosis
10.3.4. Amyotrophic Lateral Sclerosis
10.3.5. Others
10.4. Market Attractiveness Analysis By Disease Indication
11. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013 - 2017
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2018 - 2018
11.3.1. Hospitals Pharmacies
11.3.2. Retail Pharmacies & Drug Stores
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Rare Neurological Disease Market Analysis 2013-2017 and Forecast 2018-2028, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 - 2017
12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2018 - 2018
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. MEA
12.4. Market Attractiveness Analysis By Region
13. North America Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
13.1. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
13.1.1. US
13.1.2. Canada
13.2. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
13.2.1. Anti-depressants
13.2.2. Anti-psychotics
13.2.3. Cholinesterase Inhibitors
13.2.4. Biologics
13.2.5. Others (Anti-vertigo, anti-seizure)
13.3. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
13.3.1. Injectable
13.3.2. Oral
13.4. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
13.4.1. Alzheimer’s Disease
13.4.2. Narcolepsy
13.4.3. Multiple Sclerosis
13.4.4. Amyotrophic Lateral Sclerosis
13.4.5. Others
13.5. North America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
13.5.1. Hospitals Pharmacies
13.5.2. Retail Pharmacies & Drug Stores
13.5.3. Online Pharmacies
13.6. Market Attractiveness Analysis
13.6.1. By Country
13.6.2. By Drug Class
13.6.3. By Route of Administration
13.6.4. By Disease Indication
13.6.5. By Distribution Channel
13.7. Market Trends
13.8. Key Market Participants - Intensity Mapping
13.9. Drivers and Restraints - Impact Analysis
14. Latin America Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
14.1. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
14.1.1. Brazil
14.1.2. Mexico
14.1.3. Rest of Latin America
14.2. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
14.2.1. Anti-depressants
14.2.2. Anti-psychotics
14.2.3. Cholinesterase Inhibitors
14.2.4. Biologics
14.2.5. Others (Anti-vertigo, anti-seizure)
14.3. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
14.3.1. Injectable
14.3.2. Oral
14.4. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
14.4.1. Alzheimer’s Disease
14.4.2. Narcolepsy
14.4.3. Multiple Sclerosis
14.4.4. Amyotrophic Lateral Sclerosis
14.4.5. Others
14.5. Latin America Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
14.5.1. Hospitals Pharmacies
14.5.2. Retail Pharmacies & Drug Stores
14.5.3. Online Pharmacies
14.6. Market Attractiveness Analysis
14.6.1. By Country
14.6.2. By Drug Class
14.6.3. By Route of Administration
14.6.4. By Disease Indication
14.6.5. By Distribution Channel
14.7. Market Trends
14.8. Key Market Participants - Intensity Mapping
14.9. Drivers and Restraints - Impact Analysis
15. Europe Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
15.1. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
15.1.1. Germany
15.1.2. France
15.1.3. Italy
15.1.4. Denmark
15.1.5. UK
15.1.6. Russia
15.1.7. Spain
15.1.8. Rest of Europe
15.2. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
15.2.1. Anti-depressants
15.2.2. Anti-psychotics
15.2.3. Cholinesterase Inhibitors
15.2.4. Biologics
15.2.5. Others (Anti-vertigo, anti-seizure)
15.3. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
15.3.1. Injectable
15.3.2. Oral
15.4. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
15.4.1. Alzheimer’s Disease
15.4.2. Narcolepsy
15.4.3. Multiple Sclerosis
15.4.4. Amyotrophic Lateral Sclerosis
15.4.5. Others
15.5. Europe Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
15.5.1. Hospitals Pharmacies
15.5.2. Retail Pharmacies & Drug Stores
15.5.3. Online Pharmacies
15.6. Market Attractiveness Analysis
15.6.1. By Country
15.6.2. By Drug Class
15.6.3. By Route of Administration
15.6.4. By Disease Indication
15.6.5. By Distribution Channel
15.7. Market Trends
15.8. Key Market Participants - Intensity Mapping
15.9. Drivers and Restraints - Impact Analysis
16. South Asia & Oceania Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
16.1. South Asia & Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
16.1.1. India
16.1.2. Indonesia
16.1.3. Thailand
16.1.4. Malaysia
16.1.5. Rest of South Asia
16.2. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
16.2.1. Anti-depressants
16.2.2. Anti-psychotics
16.2.3. Cholinesterase Inhibitors
16.2.4. Biologics
16.2.5. Others (Anti-vertigo, anti-seizure)
16.3. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
16.3.1. Injectable
16.3.2. Oral
16.4. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
16.4.1. Alzheimer’s Disease
16.4.2. Narcolepsy
16.4.3. Multiple Sclerosis
16.4.4. Amyotrophic Lateral Sclerosis
16.4.5. Others
16.5. South Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
16.5.1. Hospitals Pharmacies
16.5.2. Retail Pharmacies & Drug Stores
16.5.3. Online Pharmacies
16.6. Market Attractiveness Analysis
16.6.1. By Country
16.6.2. By Drug Class
16.6.3. By Route of Administration
16.6.4. By Disease Indication
16.6.5. By Distribution Channel
16.7. Market Trends
16.8. Key Market Participants - Intensity Mapping
16.9. Drivers and Restraints - Impact Analysis
17. East Asia Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
17.1. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
17.1.1. China
17.1.2. Japan
17.1.3. South Korea
17.2. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
17.2.1. Anti-depressants
17.2.2. Anti-psychotics
17.2.3. Cholinesterase Inhibitors
17.2.4. Biologics
17.2.5. Others (Anti-vertigo, anti-seizure)
17.3. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
17.3.1. Injectable
17.3.2. Oral
17.4. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
17.4.1. Alzheimer’s Disease
17.4.2. Narcolepsy
17.4.3. Multiple Sclerosis
17.4.4. Amyotrophic Lateral Sclerosis
17.4.5. Others
17.5. East Asia Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
17.5.1. Hospitals Pharmacies
17.5.2. Retail Pharmacies & Drug Stores
17.5.3. Online Pharmacies
17.6. Market Attractiveness Analysis
17.6.1. By Country
17.6.2. By Drug Class
17.6.3. By Route of Administration
17.6.4. By Disease Indication
17.6.5. By Distribution Channel
17.7. Market Trends
17.8. Key Market Participants - Intensity Mapping
17.9. Drivers and Restraints - Impact Analysis
18. Oceania Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
18.1. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
18.1.1. Australia
18.1.2. New Zealand
18.2. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
18.2.1. Anti-depressants
18.2.2. Anti-psychotics
18.2.3. Cholinesterase Inhibitors
18.2.4. Biologics
18.2.5. Others (Anti-vertigo, anti-seizure)
18.3. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
18.3.1. Injectable
18.3.2. Oral
18.4. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
18.4.1. Alzheimer’s Disease
18.4.2. Narcolepsy
18.4.3. Multiple Sclerosis
18.4.4. Amyotrophic Lateral Sclerosis
18.4.5. Others
18.5. Oceania Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
18.5.1. Hospitals Pharmacies
18.5.2. Retail Pharmacies & Drug Stores
18.5.3. Online Pharmacies
18.6. Market Attractiveness Analysis
18.6.1. By Country
18.6.2. By Drug Class
18.6.3. By Route of Administration
18.6.4. By Disease Indication
18.6.5. By Distribution Channel
18.7. Market Trends
18.8. Key Market Participants - Intensity Mapping
18.9. Drivers and Restraints - Impact Analysis
19. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis and Forecast 2013-2028
19.1. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Country
19.1.1. GCC Countries
19.1.2. Northern Africa
19.1.3. South Africa
19.1.4. Rest of MEA
19.2. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Drug Class
19.2.1. Anti-depressants
19.2.2. Anti-psychotics
19.2.3. Cholinesterase Inhibitors
19.2.4. Biologics
19.2.5. Others (Anti-vertigo, anti-seizure)
19.3. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Route of Administration
19.3.1. Injectable
19.3.2. Oral
19.4. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Disease Indication
19.4.1. Alzheimer’s Disease
19.4.2. Narcolepsy
19.4.3. Multiple Sclerosis
19.4.4. Amyotrophic Lateral Sclerosis
19.4.5. Others
19.5. Middle East & Africa Rare Neurological Disease Treatment Market Value Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel
19.5.1. Hospitals Pharmacies
19.5.2. Retail Pharmacies & Drug Stores
19.5.3. Online Pharmacies
19.6. Market Attractiveness Analysis
19.6.1. By Country
19.6.2. By Drug Class
19.6.3. By Route of Administration
19.6.4. By Disease Indication
19.6.5. By Distribution Channel
19.7. Market Trends
19.8. Key Market Participants - Intensity Mapping
19.9. Drivers and Restraints - Impact Analysis
20. Global Rare Neurological Disease Treatment Market –Emerging Countries Analysis
20.1. Introduction
20.1.1. Market Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. Brazil Rare Neurological Disease Market Analysis and Forecast
20.2.1. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
20.2.1.1. By Drug Class
20.2.1.2. By Route of Administration
20.2.1.3. By Disease Indication
20.2.1.4. By Distribution Channel
20.2.2. Market Attractiveness Analysis
20.2.2.1. By Drug Class
20.2.2.2. By Route of Administration
20.2.2.3. By Disease Indication
20.2.2.4. By Distribution Channel
20.3. India Rare Neurological Disease Market Analysis and Forecast
20.3.1. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
20.3.1.1. By Drug Class
20.3.1.2. By Route of Administration
20.3.1.3. By Disease Indication
20.3.1.4. By Distribution Channel
20.3.2. Market Attractiveness Analysis
20.3.2.1. By Drug Class
20.3.2.2. By Route of Administration
20.3.2.3. By Disease Indication
20.3.2.4. By Distribution Channel
20.4. China Rare Neurological Disease Market Analysis and Forecast
20.4.1. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
20.4.1.1. By Drug Class
20.4.1.2. By Route of Administration
20.4.1.3. By Disease Indication
20.4.1.4. By Distribution Channel
20.4.2. Market Attractiveness Analysis
20.4.2.1. By Drug Class
20.4.2.2. By Route of Administration
20.4.2.3. By Disease Indication
20.4.2.4. By Distribution Channel
21. Competitive Assessment
21.1. Global Rare Neurological Disease Treatment Market Structure
21.2. Global Rare Neurological Disease Treatment Market Competition - a Dashboard View
21.3. Global Rare Neurological Disease Treatment Market Company Share Analysis
21.4. Global Rare Neurological Disease Treatment Competitor Market Footprint Matrix
21.5. Key Participants Market Presence (Intensity Mapping) by Region
22. Company Profiles
22.1. Novartis AG
22.1.1. Overview
22.1.2. Product Portfolio
22.1.3. Sales Footprint
22.1.4. Key Financials
22.1.5. Revenue Split by Segments (Product/Region)
22.1.6. Strategy Overview
22.1.7. SWOT Analysis
22.2. Pfizer, Inc.
22.2.1. Overview
22.2.2. Product Portfolio
22.2.3. Sales Footprint
22.2.4. Key Financials
22.2.5. Revenue Split by Segments (Product/Region)
22.2.6. Strategy Overview
22.2.7. SWOT Analysis
22.3. Sanofi S.A.
22.3.1. Overview
22.3.2. Product Portfolio
22.3.3. Sales Footprint
22.3.4. Key Financials
22.3.5. Revenue Split by Segments (Product/Region)
22.3.6. Strategy Overview
22.3.7. SWOT Analysis
22.4. Bayer AG
22.4.1. Overview
22.4.2. Product Portfolio
22.4.3. Sales Footprint
22.4.4. Key Financials
22.4.5. Revenue Split by Segments (Product/Region)
22.4.6. Strategy Overview
22.4.7. SWOT Analysis
22.5. Merck & Co. Inc.
22.5.1. Overview
22.5.2. Product Portfolio
22.5.3. Sales Footprint
22.5.4. Key Financials
22.5.5. Revenue Split by Segments (Product/Region)
22.5.6. Strategy Overview
22.5.7. SWOT Analysis
22.6. Allergan Plc
22.6.1. Overview
22.6.2. Product Portfolio
22.6.3. Sales Footprint
22.6.4. Key Financials
22.6.5. Revenue Split by Segments (Product/Region)
22.6.6. Strategy Overview
22.6.7. SWOT Analysis
22.7. Johnson & Johnson Services, Inc.
22.7.1. Overview
22.7.2. Product Portfolio
22.7.3. Sales Footprint
22.7.4. Key Financials
22.7.5. Revenue Split by Segments (Product/Region)
22.7.6. Strategy Overview
22.7.7. SWOT Analysis
22.8. Abbott Laboratories
22.8.1. Overview
22.8.2. Product Portfolio
22.8.3. Sales Footprint
22.8.4. Key Financials
22.8.5. Revenue Split by Segments (Product/Region)
22.8.6. Strategy Overview
22.8.7. SWOT Analysis
22.9. GlaxoSmithKline Plc
22.9.1. Overview
22.9.2. Product Portfolio
22.9.3. Sales Footprint
22.9.4. Key Financials
22.9.5. Revenue Split by Segments (Product/Region)
22.9.6. Strategy Overview
22.9.7. SWOT Analysis
22.10. Teva Pharmaceutical Industries Ltd.
22.10.1. Overview
22.10.2. Product Portfolio
22.10.3. Sales Footprint
22.10.4. Key Financials
22.10.5. Revenue Split by Segments (Product/Region)
22.10.6. Strategy Overview
22.10.7. SWOT Analysis
22.11. Sun Pharmaceutical Industries Ltd
22.11.1. Overview
22.11.2. Product Portfolio
22.11.3. Sales Footprint
22.11.4. Key Financials
22.11.5. Revenue Split by Segments (Product/Region)
22.11.6. Strategy Overview
22.11.7. SWOT Analysis
22.12. Biogen, Inc.
22.12.1. Overview
22.12.2. Product Portfolio
22.12.3. Sales Footprint
22.12.4. Key Financials
22.12.5. Revenue Split by Segments (Product/Region)
22.12.6. Strategy Overview
22.12.7. SWOT Analysis
22.13. Eisai Co., Ltd.
22.13.1. Overview
22.13.2. Product Portfolio
22.13.3. Sales Footprint
22.13.4. Key Financials
22.13.5. Revenue Split by Segments (Product/Region)
22.13.6. Strategy Overview
22.13.7. SWOT Analysis
22.14. Acer Therapeutics, Inc. (Opexa)
22.14.1. Overview
22.14.2. Product Portfolio
22.14.3. Sales Footprint
22.14.4. Key Financials
22.14.5. Revenue Split by Segments (Product/Region)
22.14.6. Strategy Overview
22.14.7. SWOT Analysis
22.15. Wockhardt Limited
22.15.1. Overview
22.15.2. Product Portfolio
22.15.3. Sales Footprint
22.15.4. Key Financials
22.15.5. Revenue Split by Segments (Product/Region)
22.15.6. Strategy Overview
22.15.7. SWOT Analysis
22.16. AB Science
22.16.1. Overview
22.16.2. Product Portfolio
22.16.3. Sales Footprint
22.16.4. Key Financials
22.16.5. Revenue Split by Segments (Product/Region)
22.16.6. Strategy Overview
22.16.7. SWOT Analysis
23. Fact.MR Research Methodology
24. Disclaimer & Contact Information
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Rare Neurological Disease Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028